Cat. No. 1496
Chemical Name: Anthra[1-9-cd]pyrazol-6(2H)-one
Biological ActivitySelective inhibitor of c-Jun N-terminal kinase (JNK). Competitively and reversibly inhibits JNK1, 2 and 3 (IC50 = 40 - 90 nM) with negligible activity at ERK2, p38β and a range of enzymes (IC50 > 10 μM). Active in vivo. Shown to have reduced selectivity over other protein kinases under certain conditions. Protects renal tubular epithelial cells against ischemia/reperfusion-induced apoptosis. Prevents BMP9-induced osteogenic differentiation of MSCs. Also available as part of the MAPK Inhibitor Tocriset™.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Bennett et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc.Natl.Acad.Sci.U.S.A. 98 13681. PMID: 11717429.
Schnabl et al (2001) TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology 34 953. PMID: 11679966.
Wang et al (2007) SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis. Life Sci. 80 2067. PMID: 17459422.
Zhao et al (2013) Activation of JNKs is essential for BMP9-induced osteogenic differentiation of mesenchymal stem cells. BMB Rep. 46 422. PMID: 23977991.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: SP 600125, supplier, selective, JNK, inhibitor, MAPK, Signaling, Signalling, c-Jun, N-Terminal, Kinase, SAPKs, Stress-Activated, Protein, Mitogen-Activated, SP600125
Find multiple products by catalog number
New Products in this Area
Potent and selective p38α inhibitorDBM 1285 dihydrochloride
p38 MAPK inhibitor; anti-inflammatorySR 3576
Highly potent and selective JNK3 inhibitorCEP 1347
Inhibitor of JNK signaling
September 8 - 9, 2014